A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

NCT04890795 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

237

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: AL8326 tablets

Sponsor

Advenchen Laboratories Nanjing Ltd.